Literature DB >> 10479511

What staging surgery should be performed on patients with uterine papillary serous carcinoma?

J P Geisler1, H E Geisler, M E Melton, M C Wiemann.   

Abstract

OBJECTIVE: While uterine papillary serous carcinoma (UPSC) is an aggressive histologic subtype, it fortunately is not as common as some other histologic subtypes. Overall, patients with UPSC have a poor survival rate. Since the optimal surgical procedure to perform on patients with this tumor is unknown, the authors wanted to determine what the optimal surgical management of patients with UPSC should be.
METHODS: All patients with the preoperative or frozen section intraoperative diagnosis of UPSC were treated with a staging or cytoreductive procedure analogous to patients with serous carcinoma of the ovary. Patients analyzed underwent surgery from March 1983 to September 1995.
RESULTS: Sixty-five patients with UPSC were found. Twenty patients had FIGO stage I tumors, 6 stage II tumors, 8 stage III tumors, and 31 stage IV tumors. Twenty-nine patients had upper abdominal disease (17 gross disease and 12 microscopic disease only). Forty-eight patients underwent pelvic and paraaortic lymphadenectomy, with 6 of 48 having positive lymph nodes. All 14 patients with lymphovascular space invasion had stage IV disease. Thirty-one of sixty-five patients had positive cytology at the time of surgery.
CONCLUSION: Based on the clinical experience of these investigators, patients with UPSC should undergo a staging laparotomy similar to the procedure undertaken for patients with ovarian carcinoma. The surgery should include at least partial omentectomy, total abdominal hysterectomy and bilateral salpingo-oophorectomy, peritoneal washings, peritoneal biopsies, and pelvic and paraaortic lymphadenectomy similar to an ovarian cancer staging procedure if no gross disease > or =2 cm is found at time of surgery. If disease > or =2 cm is found, cytoreduction should be undertaken when feasible. Copyright 1999 Academic Press.

Entities:  

Mesh:

Year:  1999        PMID: 10479511     DOI: 10.1006/gyno.1999.5513

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  5 in total

1.  Extent of lymphovascular space invasion may predict lymph node metastasis in uterine serous carcinoma.

Authors:  Yushen Qian; Erqi L Pollom; Chika Nwachukwu; Kira Seiger; Rie von Eyben; Ann K Folkins; Elizabeth A Kidd
Journal:  Gynecol Oncol       Date:  2017-07-11       Impact factor: 5.482

Review 2.  Uterine papillary serous carcinoma: state of the state.

Authors:  R Wendel Naumann
Journal:  Curr Oncol Rep       Date:  2008-11       Impact factor: 5.075

3.  An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers.

Authors:  Tilley Jenkins Vogel; Abhay Knickerbocker; Chirag A Shah; Melissa A Schiff; Christina Isacson; Rochelle L Garcia; Barbara A Goff
Journal:  J Gynecol Oncol       Date:  2014-11-06       Impact factor: 4.401

4.  Incidence of omental metastasis in uterine serous carcinoma: study protocol for a systematic review and meta-analysis.

Authors:  Cui Hu; Lin-Lin Zhang; Yu Cheng; Fei-Xue Xue; Ya Jia; Qin Zhao-Juan; Du Yi; Zhang Qian-Wen; He Yue-Dong; Zheng Ai; Yu Xu
Journal:  BMJ Open       Date:  2021-01-17       Impact factor: 2.692

5.  Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer.

Authors:  E Cocco; S Bellone; K El-Sahwi; M Cargnelutti; F Casagrande; N Buza; F A Tavassoli; E R Siegel; I Visintin; E Ratner; D-A Silasi; M Azodi; P E Schwartz; T J Rutherford; S Pecorelli; A D Santin
Journal:  Br J Cancer       Date:  2009-06-16       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.